Genomic instability in congenital lung malformations in children.


Journal

Pediatric surgery international
ISSN: 1437-9813
Titre abrégé: Pediatr Surg Int
Pays: Germany
ID NLM: 8609169

Informations de publication

Date de publication:
05 Sep 2024
Historique:
accepted: 31 08 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: epublish

Résumé

To study the biological relationship between congenital lung malformations (CLMs) and malignancy. Biopsies of 12 CPAMs, 6 intralobar sequestrations and 2 extralobar sequestrations were analyzed through whole-genome sequencing. Blood samples from 10 patients were used to confirm or exclude somatic mosaicism. Putative somatic Single Nucleotide Variants (SNVs) were called for each malformed sample with a Panel of Normals built with control DNA samples extracted from blood. The variants were subsequently confirmed by Sanger sequencing and searched, whenever possible, in the blood samples of patients. All CLMs but one presented a signature of genomic instability by means of multiple clusters of cells with gene mutations. Seven tumor transformation-related SNVs were detected in 6/20 congenital lung malformations. Four very rare in the general population SNVs were found in a region previously linked to lung cancer in 5p15.33, upstream of TERT oncogene. Furthermore, we identified missense genetic variants, whose tumorigenic role is well known, in the RET, FANCA and MET genes. Genomic instability in 95% of CLMs and genetic variants linked to tumor development in 30% of them, regardless of histopathology, are predisposing factors to malignancy, that combined with exposure to carcinogens, might trigger the development of malignancy and explain the association between CLMs and lung cancer.

Identifiants

pubmed: 39237666
doi: 10.1007/s00383-024-05835-5
pii: 10.1007/s00383-024-05835-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

248

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Pederiva F, Rothenberg SS, Hall N, Ijsselstijn H, Wong KKY, von der Thusen J, Ciet P, Achiron R, Pio d’Adamo A, Schnater JM (2023) Congenital lung malformations. Nat Rev Dis Prim 9:60
pubmed: 37919294 doi: 10.1038/s41572-023-00470-1
Raychaudhuri P, Pasupati A, James A, Whitehead B, Kumar R (2011) Prospective study of antenatally diagnosed congenital cystic adenomatoid malformations. Pediatr Surg Int 27:1159–1164
pubmed: 21519839 doi: 10.1007/s00383-011-2909-1
Hammond PJ, Devdas JM, Ray B, Ward-Platt M, Barrett AM, McKean M (2010) The outcome of expectant management of congenital cystic adenomatoid malformations (CCAM) of the lung. Eur J Pediatr Surg 20:145–149
pubmed: 20373281 doi: 10.1055/s-0030-1249047
Aziz D, Langer JC, Tuuha SE, Ryan G, Ein SH, Kim PC (2004) Perinatally diagnosed asymptomatic congenital cystic adenomatoid malformation: to resect or not? J Pediatr Surg 39:329–334
pubmed: 15017547 doi: 10.1016/j.jpedsurg.2003.11.021
Lo AY, Jones S (2008) Lack of consensus among Canadian pediatric surgeons regarding the management of congenital cystic adenomatoid malformation of the lung. J Pediatr Surg 43:797–799
pubmed: 18485941 doi: 10.1016/j.jpedsurg.2007.12.016
Singh R, Davenport M (2015) The argument for operative approach to asymptomatic lung lesions. Semin Pediatr Surg 24:187–195
pubmed: 26051052 doi: 10.1053/j.sempedsurg.2015.02.003
Patrizi S, Pederiva F, d’Adamo AP (2021) Whole-genome methylation study of congenital lung malformations in children. Front Oncol 11:689833
pubmed: 34262872 pmcid: 8273538 doi: 10.3389/fonc.2021.689833
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A et al (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452:633–637
pubmed: 18385738 doi: 10.1038/nature06885
Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T, Amos CI, Houlston RS (2008) Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40:1407–1409
pubmed: 18978787 pmcid: 2695928 doi: 10.1038/ng.273
McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D et al (2008) Lung cancer susceptibility locus at 5p15.33. Nat Genet 40:1404–1406
pubmed: 18978790 pmcid: 2748187 doi: 10.1038/ng.254
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
pubmed: 3344216 pmcid: 334765 doi: 10.1093/nar/16.3.1215
Van der Auwera GAOC, O’Connor BD (2020) Genomics in the cloud: using Docker, GATK, and WDL Terra, 1st edn. O’Reilly Media
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164
pubmed: 20601685 pmcid: 2938201 doi: 10.1093/nar/gkq603
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747–1756
pubmed: 30341162 pmcid: 6211645 doi: 10.1101/gr.239244.118
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE et al (2017) OncoKB: a precision oncology knowledge base. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00011
doi: 10.1200/PO.17.00011 pubmed: 28890946 pmcid: 5558263
Lee JK, Choi YL, Kwon M, Park PJ (2016) Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies. Annu Rev Pathol 11:283–312
pubmed: 26907526 doi: 10.1146/annurev-pathol-012615-044446
Li S, Wang W, Yu H, Zhang S, Bi W, Sun S, Hong B, Fang Z, Chen X (2023) Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma. BMC Cancer 23:1115
pubmed: 37974107 pmcid: 10655275 doi: 10.1186/s12885-023-11580-0
Cox KE, Liu S, Lwin TM, Hoffman RM, Batra SK, Bouvet M (2023) The mucin family of proteins: candidates as potential biomarkers for colon cancer. Cancers (Basel) 15:1491
pubmed: 36900282 pmcid: 10000725 doi: 10.3390/cancers15051491
Hermelijn SM, Wolf JL, Dorine den Toom T, Wijnen RMH, Rottier RJ, Schnater JM, von der Thusen JH (2020) Early KRAS oncogenic driver mutations in nonmucinous tissue of congenital pulmonary airway malformations as an indicator of potential malignant behavior. Hum Pathol 103:95–106
pubmed: 32681943 doi: 10.1016/j.humpath.2020.07.015
Rossi G, Gasser B, Sartori G, Migaldi M, Costantini M, Mengoli MC, Piccioli S, Cavazza A, Rivasi F (2012) MUC5AC, cytokeratin 20 and HER2 expression and K-RAS mutations within mucinogenic growth in congenital pulmonary airway malformations. Histopathology 60:1133–1143
pubmed: 22348416 doi: 10.1111/j.1365-2559.2011.04170.x
Chang WC, Zhang YZ, Wolf JL, Hermelijn SM, Schnater JM, von der Thusen JH, Rice A, Lantuejoul S, Mastroianni B, Farver C, Black F, Popat S, Nicholson AG (2021) Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. Histopathology 78:434–444
pubmed: 32810914 doi: 10.1111/his.14239
Hsu JS, Zhang R, Yeung F, Tang CSM, Wong JKL, So MT, Xia H, Sham P, Tam PK, Li M, Wong KKY, Garcia-Barcelo MM (2019) Cancer gene mutations in congenital pulmonary airway malformation patients. ERJ Open Res. https://doi.org/10.1183/23120541.00196-2018
doi: 10.1183/23120541.00196-2018 pubmed: 30740464 pmcid: 6360213
Lin M, Hu L, Shen S, Liu J, Liu Y, Xu Y, Chen H, Sugimoto K, Li J, Kamitsukasa I, Hiwasa T, Wang H, Xu A (2023) Atherosclerosis-related biomarker PABPC1 predicts pan-cancer events. Stroke Vasc Neurol. https://doi.org/10.1136/svn-2022-002246
doi: 10.1136/svn-2022-002246 pubmed: 37185136 pmcid: 11221298
Podlevsky JD, Chen JJ (2012) It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res 730:3–11
pubmed: 22093366 doi: 10.1016/j.mrfmmm.2011.11.002
Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791
pubmed: 9282118 doi: 10.1016/S0959-8049(97)00062-2
Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425
pubmed: 12208997 pmcid: 120798 doi: 10.1128/MMBR.66.3.407-425.2002
Hahn WC, Meyerson M (2001) Telomerase activation, cellular immortalization and cancer. Ann Med 33:123–129
pubmed: 11327115 doi: 10.3109/07853890109002067
Zhu J, Zhao Y, Wang S (2010) Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 1:22–32
pubmed: 21203995 pmcid: 3683535 doi: 10.1007/s13238-010-0014-1
Cortez Cardoso Penha R, Smith-Byrne K, Atkins JR, Haycock PC, Kar S, Codd V, Samani NJ, Nelson C, Milojevic M, Gabriel AAG, Amos C, Brennan P, Hung RJ, Kachuri L, McKay JD (2023) Common genetic variations in telomere length genes and lung cancer: a Mendelian randomisation study and its novel application in lung tumour transcriptome. Elife 12:e83118
pubmed: 37079368 pmcid: 10118386 doi: 10.7554/eLife.83118
Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360–366
pubmed: 24018021 doi: 10.1016/j.eururo.2013.08.052
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959
pubmed: 23348506 pmcid: 4423787 doi: 10.1126/science.1229259
Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Maximo V, Sobrinho-Simoes M, Soares P (2014) Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch 465:119–133
pubmed: 25048572 doi: 10.1007/s00428-014-1608-4
Ni Z, Tao K, Chen G, Chen Q, Tang J, Luo X, Yin P, Tang J, Wang X (2012) CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS ONE 7:e52598
pubmed: 23300716 pmcid: 3530437 doi: 10.1371/journal.pone.0052598
James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M (2012) Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS ONE 7:e36116
pubmed: 22675468 pmcid: 3366984 doi: 10.1371/journal.pone.0036116
Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774
pubmed: 9506724
Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH (1997) A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176–4178
pubmed: 9398735
Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM (2005) RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65:1729–1737
pubmed: 15753368 doi: 10.1158/0008-5472.CAN-04-2363
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381
pubmed: 22327623 doi: 10.1038/nm.2658
Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865–875
pubmed: 23814043 pmcid: 3720641 doi: 10.1634/theoncologist.2013-0095
Sipeki S, Bander E, Buday L, Farkas G, Bacsy E, Ways DK, Farago A (1999) Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 11:885–890
pubmed: 10659996 doi: 10.1016/S0898-6568(99)00060-1
Van Der Steen N, Pauwels P, Gil-Bazo I, Castanon E, Raez L, Cappuzzo F, Rolfo C (2015) cMET in NSCLC: can we cut off the head of the hydra? From the pathway to the resistance. Cancers (Basel) 7:556–573
pubmed: 25815459 doi: 10.3390/cancers7020556
Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272–6281
pubmed: 14559814
Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R (2009) Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15:5714–5723
pubmed: 19723643 pmcid: 2767337 doi: 10.1158/1078-0432.CCR-09-0070
Fanconi G (1967) Familial constitutional panmyelocytopathy, Fanconi’s anemia (F.A.) I. clinical aspects. Semin Hematol 4:233–240
pubmed: 6074578
Savino M, Borriello A, D’Apolito M, Criscuolo M, Del Vecchio M, Bianco AM, Di Perna M, Calzone R, Nobili B, Zatterale A, Zelante L, Joenje H, Della Ragione F, Savoia A (2003) Spectrum of FANCA mutations in Italian Fanconi anemia patients: identification of six novel alleles and phenotypic characterization of the S858R variant. Hum Mutat 22:338–339
pubmed: 12955722 doi: 10.1002/humu.9180
Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J (2010) A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosom Cancer 49:342–352
pubmed: 20073072 doi: 10.1002/gcc.20746
Casagrande A, Pederiva F (2016) Association between congenital lung malformations and lung tumors in children and adults: a systematic review. J Thorac Oncol 11:1837–1845
pubmed: 27423390 doi: 10.1016/j.jtho.2016.06.023

Auteurs

Ronald Rodrigues de Moura (R)

Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.

Sara Patrizi (S)

University of Trieste, Trieste, Italy.

Emmanouil Athanasakis (E)

Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.

Jurgen Schleef (J)

Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.

Federica Pederiva (F)

Pediatric Surgery, "F. Del Ponte" Hospital, ASST Settelaghi, Via Filippo del Ponte 19, 21100, Varese, Italy. federica_pederiva@yahoo.it.

Adamo Pio d'Adamo (AP)

Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH